• Pedro N Aguiar, Ramon Andrade De Mello, Peter Hall, Hakaru Tadokoro, and Lima LopesGilberto deGSylvester Comprehensive Cancer Center at the University of Miami, Miami, FL 33136, USA..
• Division of Medical Oncology, Federal University of São Paulo, São Paulo, SP, Brazil.
• Immunotherapy. 2017 May 1; 9 (6): 499-506.

AimThe treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data.MethodsWe searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis.Results14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).ConclusionPD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.

36 keywords...

hide…